Phreesia, Inc. (PHR)
NYSE: PHR · Real-Time Price · USD
10.84
-0.26 (-2.34%)
Sep 4, 2026, 1:36 PM EDT - Market open
Phreesia Revenue
Phreesia had revenue of $129.46M in the quarter ending July 31, 2026, with 10.41% growth. This brings the company's revenue in the last twelve months to $507.79M, up 12.93% year-over-year. In the fiscal year ending January 31, 2026, Phreesia had annual revenue of $480.59M with 14.48% growth.
Revenue (ttm)
$507.79M
Revenue Growth
+12.93%
P/S Ratio
1.35
Revenue / Employee
$283,842
Employees
1,789
Market Cap
670.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2026 | 480.59M | 60.78M | 14.48% |
| Jan 31, 2025 | 419.81M | 63.51M | 17.83% |
| Jan 31, 2024 | 356.30M | 75.39M | 26.84% |
| Jan 31, 2023 | 280.91M | 67.68M | 31.74% |
| Jan 31, 2022 | 213.23M | 64.56M | 43.42% |
| Jan 31, 2021 | 148.68M | 23.89M | 19.15% |
| Jan 31, 2020 | 124.78M | 24.90M | 24.92% |
| Jan 31, 2019 | 99.89M | 20.06M | 25.12% |
| Jan 31, 2018 | 79.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.49B |
| Evolent Health | 2.10B |
| Claritev | 994.67M |
| GoodRx Holdings | 785.23M |
| Certara | 421.75M |
| HealthStream | 321.12M |
| Omada Health | 309.76M |
| Weave Communications | 257.79M |
PHR News
- 4 hours ago - Phreesia price target lowered to $13 from $14 at DA Davidson - TheFly
- 6 hours ago - Phreesia price target raised to $11 from $10 at Baird - TheFly
- 20 hours ago - Phreesia files automatic mixed securities shelf - TheFly
- 1 day ago - Phreesia price target raised to $10 from $9 at Wells Fargo - TheFly
- 1 day ago - Phreesia Earnings Call Transcript: Q2 2027 - Transcripts
- 1 day ago - Phreesia Earnings release: Q2 2027 - Filings
- 1 day ago - Phreesia Slides: Q2 2027 - Filings
- 1 day ago - Phreesia Shareholder letter: Q2 2027 - Filings